Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ascendis Pharma ADR
(NQ:
ASND
)
139.68
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma ADR
< Previous
1
2
3
4
5
6
Next >
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
August 13, 2024
Via
Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
August 12, 2024
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient...
Via
Benzinga
Exposures
Product Safety
Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug
August 12, 2024
The company faced a number of regulatory setbacks that pushed its initial expected approval date out from April.
Via
Investor's Business Daily
Exposures
Product Safety
$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today
August 09, 2024
Via
Benzinga
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
July 18, 2024
Via
Benzinga
Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
July 03, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
June 26, 2024
Via
Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
May 31, 2024
Via
Benzinga
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
July 05, 2024
U.S. stock futures rise, Macy's receives higher offer, LGI Homes sells 571 homes, Telefonaktiebolaget records impairment charge, GFL declares dividend.
Via
Benzinga
(ASND) - Analyzing Ascendis Pharma's Short Interest
May 28, 2024
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
May 17, 2024
Via
Benzinga
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
May 15, 2024
Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to...
Via
Benzinga
Exposures
Product Safety
Masters In Trading - Saturday, May 11
May 11, 2024
In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week.
Via
Talk Markets
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
May 06, 2024
Via
Benzinga
ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024
May 02, 2024
Ascendis Pharma just reported results for the first quarter of 2024.
Via
InvestorPlace
Looking Into Ascendis Pharma's Recent Short Interest
April 26, 2024
Via
Benzinga
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
April 18, 2024
Via
Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
April 03, 2024
Via
Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
March 14, 2024
Via
Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
March 09, 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...
Via
Talk Markets
These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher
March 03, 2024
Ethan Meyers, the research director at Westfield Capital Management, has a knack for identifying promising investments that have proven fruitful, especially for the Harbor Small Cap Growth Fund, where...
Via
Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
February 23, 2024
Via
Benzinga
How Is The Market Feeling About Ascendis Pharma?
February 13, 2024
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today
February 08, 2024
Via
Benzinga
Earnings Scheduled For February 7, 2024
February 07, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.
Via
Benzinga
Ascendis Pharma's Earnings: A Preview
February 06, 2024
Via
Benzinga
$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today
February 02, 2024
Via
Benzinga
Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
December 19, 2023
Ascendis Pharma A/S (NASDAQ: ASND) released topline results from Phase 3 foresiGHt trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth...
Via
Benzinga
Analyst Expectations for Ascendis Pharma's Future
November 09, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.